Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (371-380 of 1,211) with videos related to

Pageof 122
Sort By:
American Journal of Hypertension|September 10, 2015
Prehypertension is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities StudyAngela B S Santos, Deepak K Gupta, Natalie A Bello, et al.
Circulation. Heart Failure|October 5, 2020
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/ValsartanNasrien E Ibrahim, Ileana L Piña, Alexander Camacho, et al.
JAMA|November 13, 2019
Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced CardiomyopathyJagmeet P Singh, Scott D Solomon, Michael G Fradley, et al.
Journal of the American Heart Association|March 7, 2022
Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older AdultsRiccardo M Inciardi, Brian Claggett, Deepak K Gupta, et al.
JAMA Cardiology|July 21, 2016
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection FractionThomas A Gaziano, Gregg C Fonarow, Brian Claggett, et al.
Lancet (London, England)|August 31, 2012
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialScott D Solomon, Michael Zile, Burkert Pieske, et al.
European Journal of Heart Failure|February 7, 2024
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathyPablo Garcia-Pavia, Martha Grogan, Parag Kale, et al.
American Heart Journal|May 24, 2025
Structural abnormalities and effects of sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trialVeraprapas Kittipibul, Derek D Cyr, Josephine Harrington, et al.
Journal of the American College of Cardiology|February 19, 2013
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery diseaseTorbjørn Omland, Marc A Pfeffer, Scott D Solomon, et al.
European Journal of Heart Failure|November 29, 2019
Left atrial structure and function and the risk of death or heart failure in atrial fibrillationRiccardo M Inciardi, Robert P Giugliano, Brian Claggett, et al.
Pageof 122

Showing results (371-380 of 1,211) with videos related to

Sort By:
Pageof 122
American Journal of Hypertension|September 10, 2015
Prehypertension is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities StudyAngela B S Santos, Deepak K Gupta, Natalie A Bello, et al.
Circulation. Heart Failure|October 5, 2020
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/ValsartanNasrien E Ibrahim, Ileana L Piña, Alexander Camacho, et al.
JAMA|November 13, 2019
Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced CardiomyopathyJagmeet P Singh, Scott D Solomon, Michael G Fradley, et al.
Journal of the American Heart Association|March 7, 2022
Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older AdultsRiccardo M Inciardi, Brian Claggett, Deepak K Gupta, et al.
JAMA Cardiology|July 21, 2016
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection FractionThomas A Gaziano, Gregg C Fonarow, Brian Claggett, et al.
Lancet (London, England)|August 31, 2012
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialScott D Solomon, Michael Zile, Burkert Pieske, et al.
European Journal of Heart Failure|February 7, 2024
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathyPablo Garcia-Pavia, Martha Grogan, Parag Kale, et al.
American Heart Journal|May 24, 2025
Structural abnormalities and effects of sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trialVeraprapas Kittipibul, Derek D Cyr, Josephine Harrington, et al.
Journal of the American College of Cardiology|February 19, 2013
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery diseaseTorbjørn Omland, Marc A Pfeffer, Scott D Solomon, et al.
European Journal of Heart Failure|November 29, 2019
Left atrial structure and function and the risk of death or heart failure in atrial fibrillationRiccardo M Inciardi, Robert P Giugliano, Brian Claggett, et al.
Pageof 122